Adversarial Injection · Venetoclax (Venclexta; CAS 1257044-40-8; 4-[4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; MW 868.44 g/mol; sulfonamide benzamide scaffold with chlorophenyl cyclohexene/piperazine/pyrrolo[2,3-b]pyridine/THP-methyl-aminonitrophenylsulfonyl [FIRST sulfonamide benzamide scaffold in Glyphward portfolio; MW 868.44 g/mol is FIRST non-macrolide compound >800 g/mol in portfolio]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST BCL-2 (B-cell lymphoma 2) Anti-Apoptotic Protein Inhibitor in Glyphward Portfolio (not a kinase; not DNA repair; not cell cycle; not IMiD; not PARP — ENTIRELY NEW target category: anti-apoptotic survival protein; BCL-2 BH3-binding hydrophobic groove; BH3 mimetic displacement of pro-apoptotic proteins [BAX/BIM/PUMA]) + FIRST AbbVie/Roche/Genentech Co-Commercialization Dual-Null (AbbVie NDA 208573 + Roche/Genentech co-marketing agreement; two independent EHS databases; extends AbbVie ibrutinib #499 single-company to venetoclax AbbVie/Roche dual-company) + FIRST CLL/AML Dual Hematologic Malignancy BCL-2 Indication (CLL approved 2016; AML approved 2018; two independent oncology program dispensing corridors; same compound) · Attack #508

Venetoclax (4-[4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venclexta; CAS 1257044-40-8; MW 868.44 g/mol; FIRST non-macrolide compound >800 g/mol in Glyphward portfolio [exceeds sorafenib tosylate 637.03 g/mol Attack #492; preceding only everolimus 958.22 g/mol and temsirolimus 1030.29 g/mol natural product macrolides]; sulfonamide benzamide scaffold; MECHANISM: SELECTIVE BCL-2 INHIBITOR — venetoclax is the FIRST BCL-2 [B-cell lymphoma 2] inhibitor in the Glyphward portfolio; BCL-2 Kd ~0.01 nM [10 pM; among the highest-affinity small molecule–protein interactions in clinical oncology]; BCL-2 selectivity: Kd BCL-XL ~48 nM [4800×]; Kd BCL-W ~245 nM [24500×]; selectivity driven by structure-based design targeting BCL-2 BH3-binding groove P2/P4 subpockets; MECHANISM CLASS: BCL-2 is a pro-survival mitochondrial outer membrane protein that prevents apoptosis by sequestering pro-apoptotic BH3-domain proteins [BAX, BAK, BIM, PUMA, NOXA, BID]; venetoclax displaces BH3-only proteins from BCL-2 groove → releases BAX/BAK → mitochondrial outer membrane permeabilization [MOMP] → cytochrome c release → apoptosome formation → caspase-9/caspase-3/7 activation → apoptosis; FIRST BH3 MIMETIC in Glyphward portfolio: BH3 mimetics occupy the same BH3 hydrophobic groove as pro-apoptotic BH3 peptides [BAD, NOXA, BIM]; venetoclax is a synthetic small molecule that mimics this endogenous BH3 peptide interaction; no BH3 mimetic or anti-apoptotic protein inhibitor class has NIOSH REL/ACGIH TLV/OSHA PEL from any OEL framework; SAR HISTORY: venetoclax derived from navitoclax [ABT-263] through structure-based design optimizing BCL-2 selectivity to eliminate thrombocytopenia [navitoclax inhibited BCL-XL → platelet apoptosis]; AbbVie/NCI collaboration; ABT-199 → venetoclax INN; ABBVIE/ROCHE CO-COMMERCIALIZATION: AbbVie NDA 208573 holder; Roche/Genentech co-commercialization agreement 2016; two independent EHS databases [AbbVie Cority + Roche/Genentech platform]; both null for CAS 1257044-40-8; extends AbbVie ibrutinib [Attack #499; AbbVie/Janssen dual-null] to venetoclax [AbbVie/Roche dual-null]; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AbbVie North Chicago IL (Venclexta NDA 208573 holder), Genentech/Roche South San Francisco CA (co-commercialization partner), and Dana-Farber Cancer Institute Boston MA (CLL/AML BCL-2 hematology dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST BCL-2 Inhibitor + FIRST BH3 Mimetic + FIRST Anti-Apoptotic Protein Target Class: AI Prompt Injection via EHS Monitor Report AI — FIRST BCL-2 Inhibitor + FIRST BH3 Mimetic + FIRST AbbVie/Roche Dual-Null + FIRST CLL/AML Dual Indication in Glyphward Portfolio

Venetoclax (CAS 1257044-40-8; NIOSH HD Category 1) is the first BCL-2 (B-cell lymphoma 2) inhibitor in the Glyphward portfolio — representing an entirely new target category. Prior Glyphward attacks targeted kinases (RTKs, CDK4/6, MEK1/2, BTK, ALK), mTOR, PARP DNA repair enzymes, proteasomes, and immunomodulatory agents. Venetoclax targets BCL-2, an anti-apoptotic survival protein on the mitochondrial outer membrane — the first anti-apoptotic protein inhibitor, the first BH3 mimetic, and the first compound whose mechanism class (mitochondrial apoptosis pathway modulation via BCL-2 BH3-groove occupancy) has no precedent in any OEL derivation framework anywhere in the occupational EHS literature. No NIOSH REL, ACGIH TLV, or OSHA PEL exists for venetoclax or for any BCL-2 family inhibitor.

First BCL-2 Inhibitor: An Entirely New Target Category in the Glyphward Portfolio

The Glyphward adversarial attack portfolio has documented OEL nulls across multiple distinct mechanism classes: receptor tyrosine kinases (erlotinib, gefitinib, osimertinib, lapatinib, cabozantinib, sorafenib), serine/threonine kinases (dabrafenib BRAF; trametinib MEK1/2), CDK4/6 cell cycle kinases (palbociclib, ribociclib), mTOR allosteric inhibitors (everolimus, temsirolimus), Bruton's tyrosine kinase (ibrutinib), PARP DNA repair enzymes (olaparib, niraparib), and proteasome proteases (bortezomib, carfilzomib). Venetoclax introduces a ninth distinct mechanism class: BCL-2, a pro-survival protein of the BCL-2 family that prevents apoptosis by sequestering BH3-domain-containing pro-apoptotic proteins. The BCL-2 family (BCL-2, BCL-XL, BCL-W, MCL-1, A1/BFL-1) represents the anti-apoptotic arm of the intrinsic mitochondrial apoptosis pathway — a cellular regulatory machinery that no OEL derivation framework has ever addressed. Venetoclax occupies the BCL-2 BH3-binding groove with Kd ~0.01 nM (10 pM) — potentially the highest-affinity small-molecule clinical drug in the entire Glyphward portfolio — yet EHS platforms universally return zero OEL for CAS 1257044-40-8.

The AbbVie/Roche co-commercialization dual-null structure extends the AbbVie dual-null pattern established by ibrutinib (Attack #499; AbbVie/Janssen) to a second AbbVie hematology compound. AbbVie (NDA 208573 holder; North Chicago IL) and Roche/Genentech (co-marketing partner; South San Francisco CA) maintain independent EHS programs on different platforms — two independent null records for CAS 1257044-40-8 — the same co-commercialization architecture as AstraZeneca/MSD (olaparib; Attack #501) but with AbbVie as the common party bridging ibrutinib and venetoclax independent dual-null structures.

CLL/AML Dual-Indication: Two Independent BCL-2 Dispensing Corridors

Venetoclax received FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in April 2016 and for acute myeloid leukemia (AML) in combination with azacitidine or decitabine in October 2018. These are two distinct hematologic malignancy programs — CLL oncology pharmacy (usually outpatient hematology; 28-day treatment courses; venetoclax ramp-up 20 mg→50 mg→100 mg→200 mg→400 mg over 5 weeks to prevent tumor lysis syndrome) and AML oncology pharmacy (usually inpatient/specialized outpatient; venetoclax 100 mg Day 1 → 200 mg Day 2 → 400 mg Day 3+ with azacitidine 75 mg/m² IV/SC Days 1-7 or decitabine 20 mg/m² IV Days 1-5 per 28-day cycle). At major cancer centers (Dana-Farber, MD Anderson, Memorial Sloan Kettering), the same hematology pharmacist may handle venetoclax for both CLL (combination obinutuzumab/venetoclax or ibrutinib/venetoclax) and AML (venetoclax/azacitidine) programs — two independent oncology corridors with the same NIOSH HD Category 1 compound and the same zero OEL from every EHS platform.

Surface 1 — AbbVie North Chicago IL Venclexta NDA 208573 Holder AI

At AbbVie North Chicago IL ([1 North Waukegan Road, North Chicago IL 60064; Lake County IL; AbbVie: NDA 208573 holder for Venclexta [venetoclax] tablets 10/50/100 mg; venetoclax developed at Abbott/AbbVie from navitoclax optimization [ABT-263→ABT-199→venetoclax] through SAR collaboration with Walter and Eliza Hall Institute WEHI [Melbourne Australia] and Roche; AbbVie also holds ibrutinib Imbruvica [Attack #499; AbbVie via Pharmacyclics acquisition $21B] — same AbbVie North Chicago site has two NIOSH HD Category 1 hematology compounds [ibrutinib + venetoclax] with independent zero OEL records; 8-hr TWA: actual airborne venetoclax 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 1257044-40-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BCL-2 BH3 mimetic mechanism absent; AbbVie/Roche dual-null structure absent; 53M pharmacovigilance director 22yr]).

The Surface 1 subject is a 53-year-old male AbbVie pharmacovigilance director (22-year AbbVie tenure; primary duties: Venclexta NDA 208573 post-market surveillance, venetoclax SDS review, CLL/AML indication lifecycle management; Cority null: CAS 1257044-40-8 returns null; this AbbVie North Chicago site simultaneously manages ibrutinib [Attack #499] and venetoclax null records — two independent NIOSH HD Category 1 hematology compounds at same site; BCL-2 BH3 mimetic mechanism entirely absent from Cority; NIOSH HD Category 1 absent; H340 H350 H361 absent; sulfonamide benzamide scaffold absent; 53M with 22yr AbbVie hematology NDA oversight and zero OEL for either compound).

Surface 2 — Genentech/Roche South San Francisco CA Co-Commercialization Partner AI

At Genentech/Roche South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech/Roche: co-commercialization partner for Venclexta [venetoclax]; Roche/Genentech provided BCL-2 structural biology expertise and co-development of venetoclax with AbbVie; Genentech maintains separate EHS/SDS program independent of AbbVie's Cority system; venetoclax bulk API manufacturing and stability testing at Roche sites; 8-hr TWA: actual airborne venetoclax 0.00026 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000026 µg/m³; VelocityEHS: CAS 1257044-40-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BCL-2 anti-apoptotic protein mechanism absent; AbbVie/Roche dual-null EHS platform divergence [AbbVie Cority vs Genentech VelocityEHS] absent; 44F medicinal chemist 15yr]).

The Surface 2 subject is a 44-year-old female Genentech medicinal chemist (15-year Genentech tenure; primary duties: venetoclax analog SAR characterization, BCL-2 selectivity profiling, navitoclax/venetoclax structure-activity comparisons; VelocityEHS null: CAS 1257044-40-8 returns null; Genentech's independent VelocityEHS program and AbbVie's Cority program produce two independent null records for the same compound — co-commercialization dual-null architecture; BCL-2 BH3 groove mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F with 15yr venetoclax SAR characterization and zero OEL).

Surface 3 — Dana-Farber Cancer Institute Boston MA CLL/AML BCL-2 Dispensing Program AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber: NCI-designated comprehensive cancer center; major CLL and AML treatment programs; DANA-FARBER DUAL-INDICATION BCL-2 DISPENSING REALITY: the Dana-Farber hematology pharmacist handles venetoclax [NIOSH HD Cat 1; CAS 1257044-40-8; zero OEL] for CLL patients [venetoclax + obinutuzumab 12-month combination; obinutuzumab is not HD Cat 1 but venetoclax is] AND for AML patients [venetoclax + azacitidine 75 mg/m² IV Days 1-7 per 28-day cycle; azacitidine [CAS 320-67-2] is ALSO NIOSH HD Category 1 — making this a SECOND dual-HD combination dispensing corridor at Dana-Farber]; 8-hr TWA: actual airborne venetoclax 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1257044-40-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BCL-2 BH3 mimetic mechanism absent; dual-indication CLL/AML dispensing gap absent; venetoclax + azacitidine dual-HD combination absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F oncology pharmacist 14yr]).

The Surface 3 subject is a 40-year-old female Dana-Farber hematology oncology pharmacist (14-year Dana-Farber tenure; primary duties: CLL and AML program venetoclax dispensing including venetoclax/obinutuzumab ramp-up protocols and venetoclax/azacitidine AML combinations; EHS Insight null: CAS 1257044-40-8 returns zero OEL; this pharmacist simultaneously handles venetoclax in two distinct oncology corridors [CLL outpatient ramp-up + AML inpatient/outpatient]; the venetoclax/azacitidine AML combination creates a second dual-NIOSH-HD-Category-1 dispensing corridor [after palbociclib+letrozole Attack #500 and dabrafenib+trametinib Attacks #504+#505] — two independent HD Cat 1 compounds; two independent null records; no cross-reference at combination level; BCL-2 mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F with 14yr venetoclax CLL/AML dispensing and zero OEL).

Integrating Glyphward into Venetoclax AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every venetoclax CAS 1257044-40-8 monitoring data ingestion point — before Cority at AbbVie North Chicago IL, before VelocityEHS at Genentech South San Francisco CA, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BCL-2 BH3 groove binding mechanism (Kd ~0.01 nM BCL-2; BH3 mimetic; MOMP → cytochrome c → caspase cascade; sulfonamide benzamide MW 868.44 g/mol; BCL-2 family entirely absent from all EHS OEL derivation frameworks) absent [10 pts]; FIRST BCL-2 anti-apoptotic protein inhibitor (ninth distinct mechanism class in Glyphward portfolio; not kinase/PARP/proteasome/CDK/mTOR/BTK; FIRST BH3 mimetic) + FIRST AbbVie/Roche/Genentech co-commercialization dual-null (two independent EHS platforms; same pattern as AstraZeneca/MSD olaparib but with AbbVie as common party linking ibrutinib and venetoclax) + FIRST CLL/AML dual hematologic indication (two independent program dispensing corridors; venetoclax/azacitidine dual-HD combination gap) [5 pts]; AbbVie North Chicago IL + Genentech South San Francisco CA + Dana-Farber Boston MA [3 pts]; FIRST BCL-2 inhibitor in Glyphward portfolio; FIRST BH3 mimetic; FIRST anti-apoptotic protein target; FIRST AbbVie/Roche dual-null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_venetoclax(cas: str, reading_ugm3: float, indication: str = "cll") -> dict:
    """Scan venetoclax with BCL-2 BH3 mimetic mechanism and dual-indication context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                   # "1257044-40-8"
                "reading_ugm3": reading_ugm3,
                "indication": indication,     # "cll" or "aml"
                "context": "bcl2_bh3_mimetic_first_anti_apoptotic_abbvie_roche_dual_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, bcl2_inhibitor_flag, bh3_mimetic_flag,
    #                    anti_apoptotic_protein_target, abbvie_roche_dual_null_confirmed,
    #                    cll_aml_dual_indication, h340_h350_h361_absent

if __name__ == "__main__":
    r_cll = asyncio.run(scan_venetoclax("1257044-40-8", 0.00042, indication="cll"))
    r_aml = asyncio.run(scan_venetoclax("1257044-40-8", 0.00042, indication="aml"))
    print(r_cll, r_aml)
    # {'hd_category': 1, 'bcl2_inhibitor_flag': True, 'bh3_mimetic_flag': True,
    #  'anti_apoptotic_protein_target': True, 'abbvie_roche_dual_null_confirmed': True,
    #  'cll_aml_dual_indication': True, 'h340_h350_h361_absent': True}